U.S. Dupixent Market (2025 - 2033) Size, Share & Trends Analysis Report By Indication (Atopic Dermatitis, Asthma, Chronic Rhinosinusitis with Nasal Polyps, Chronic Obstructive Pulmonary Disease, Bullous Pemphigoid), By Distribution Channel, By Region, And Segment Forecasts

U.S. Dupixent Market Summary

The U.S. dupixent market size was estimated at USD 10.39 billion in 2024 and is projected to reach USD 16.82 billion by 2033, growing at a CAGR of 5.47% from 2025 to 2033. The market growth dominates due to high healthcare access in the U.S.

The U.S. dupixent industry is driven by the rising prevalence of chronic inflammatory conditions, including atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps (CRSwNP). The recent FDA approval for chronic obstructive pulmonary disease (COPD) in September 2024, particularly in adolescent patients, has expanded the drug’s therapeutic scope.

Dupixent, a monoclonal antibody targeting interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways, addresses unmet clinical needs in moderate-to-severe inflammatory diseases. Its demonstrated efficacy in atopic dermatitis and severe asthma has positioned it as a leading biologic in the U.S. market.

Healthcare infrastructure and expenditure trends support the drug’s adoption. The U.S. recorded USD 4.9 trillion in healthcare spending in 2023, driven by increasing biologic uptake and demand for specialty care. However, 26 million uninsured Americans and reimbursement gaps remain a constraint on market reach. Despite these limitations, telehealth adoption, utilized by 20% of patients, has improved access in urban settings. In contrast, rural areas, which account for 19% of the population, continue to face access limitations.

The aging population, with 58 million Americans over the age of 65, is contributing to rising COPD prevalence, further supporting demand. In addition, the annual 2% rise in atopic dermatitis and asthma cases, largely due to environmental factors, reinforces market growth.

Dupixent’s subcutaneous administration and favorable safety profile compared to corticosteroids improve patient compliance. Real-world evidence studies, backed by Sanofi and the market, are supported by emerging pipeline innovations such as eosinophilic esophagitis, optimized dosing regimens, and expanded manufacturing capacity. However, high treatment costs and coverage limitations in underserved regions pose challenges. Strategic collaborations and patient assistance programs are being implemented to address these barriers, sustaining growth momentum through 2033.

Pipeline Analysis

Sanofi and Regeneron are advancing Dupixent’s pipeline with clinical trials exploring new indications and optimized formulations. Phase III trials for eosinophilic esophagitis (EoE) and prurigo nodularis show promising efficacy, with potential FDA submissions. Studies evaluating Dupixent in combination with other biologics for severe asthma aim to enhance treatment outcomes.

Based on these positive phase 3 results, the U.S. Food and Drug Administration (FDA) approved Dupixent on April 18, 2025, as the first new targeted therapy for CSU in over a decade. This approval covers adults and adolescents aged 12 years and older whose symptoms are not adequately controlled by H1 antihistamines, potentially expanding the patient pool. Pediatric trials for eosinophilic esophagitis address unmet needs in younger populations, while studies in bullous pemphigoid, recently approved, target rare diseases. These developments could increase market penetration by addressing unmet needs in niche indications, with projected revenue growth from new indications by 2033.

Currently, there are early trials for conditions like chronic urticaria and allergic fungal rhinosinusitis, with initial results showing promise. With strong investment in research and development, Dupixent is well positioned to remain a leader in the market. If all goes well and approvals are granted, we could see its market share grow by 2033.

Patent & Exclusivity Summary Dupixent Market

Market Concentration & Characteristics

The U.S. dupixent industry is highly innovative, driven by Sanofi and Regeneron’s focus on expanding indications and improving delivery systems. Dupixent’s targeting of IL-4 and IL-13 pathways represents a breakthrough in treating inflammatory diseases. Innovation drives the Dupixent market, with Sanofi and Regeneron advancing new indications like chronic spontaneous urticaria through trials such as LIBERTY-CSU CUPID, which received FDA approval in April 2025. Ongoing trials for eosinophilic esophagitis and chronic urticaria reflect continuous R&D efforts. Development of auto-injectors and pediatric formulations enhances patient access. Real-world evidence studies provide data on long-term efficacy, supporting prescriber adoption.

High barriers to entry characterize the U.S. dupixent industry. Developing biologics requires substantial investment, with R&D and manufacturing costs exceeding USD 1 billion. Stringent FDA requirements for clinical trials and safety data deter smaller players. Dupixent’s extensive patent portfolio, with exclusivities, limits generic competition. Established relationships between Sanofi, Regeneron, and payers create reimbursement challenges for new entrants. Brand loyalty among prescribers, built on Dupixent’s proven efficacy, further restricts market access. However, biosimilar development may emerge post-2034, potentially lowering barriers if cost-effective alternatives gain FDA approval.

FDA regulations significantly influence the U.S. dupixent industry. Strict approval processes ensure safety and effectiveness, with the recent COPD approval in September 2024 broadening market scope. Post-marketing surveillance requires long-term safety data, raising compliance costs. Reimbursement policies through Medicare and private payers impact pricing and access, creating challenges.

Substitutes for Dupixent include corticosteroids, other biologics, and emerging therapies. Corticosteroids, widely used for atopic dermatitis and asthma, are less effective and have significant side effects, limiting their appeal. Biologics like Xolair and Fasenra compete in asthma and CRSwNP, but Dupixent’s broader indication coverage and superior efficacy, demonstrated in 2025 EAACI data, reduce substitution risk. JAK inhibitors for atopic dermatitis face safety concerns, constraining their adoption.

Indication Insights

The atopic dermatitis segment led the market with the largest revenue share of 73.30% in 2024, driven by high prevalence (73% of U.S. adults) and strong efficacy in moderate-to-severe cases. Dupixent’s efficacy in moderate-to-severe cases, reducing itch and lesions by 70% in clinical trials, supports its dominance. Urban healthcare access and insurance coverage, with 65% of prescriptions covered by private plans, sustains its market position. Growth is limited by high costs (USD 40,000/year) and access barriers for 15% of uninsured patients. Data sourced from CDC prevalence reports and Grand View Research.

The chronic obstructive pulmonary disease (COPD) segment is anticipated to grow at the fastest CAGR during the forecast period, driven by an estimated 16 million diagnosed cases. The FDA’s approval of Dupixent for adolescent patients in September 2024 has notably expanded the eligible treatment population, reinforcing market momentum. Increasing disease burden among aging individuals and exposure to environmental risk factors such as air pollution and smoking are key contributors to rising COPD incidence. These trends are boosting demand for targeted biologic therapies. Dupixent’s ability to address severe, uncontrolled COPD symptoms positions it as a valuable therapeutic option in this expanding segment.

Distribution Channel Insights

The hospital pharmacies segment led the market with the largest revenue share of 55.08% in 2024, driven by their role in administering biologics for severe conditions. With 6,093 U.S. hospitals, supported by reimbursement structures that favor inpatient settings. Specialists in hospitals ensure proper administration of CRSwNP and asthma patients. Supply chain stability, backed by Sanofi’s manufacturing investments, meets demand. Challenges include high costs and prior authorization delays, affecting hospital-based prescriptions. Growth is steady, reflecting reliance on hospital infrastructure. 

The other segment, including online pharmacies, is anticipated to grow at the fastest CAGR during the forecast period as telehealth integration drives Dupixent refills. Patient convenience and urban adoption, where 80% of users reside, fuel growth. Regulatory hurdles and insurance verification. Expansion is supported by rising disease awareness and digital health trends. Rural access remains limited, with fewer online pharmacy users in these areas. Projected growth aligns annual prescription increase.

Key U.S. Dupixent Company Insights

Sanofi and Regeneron operate a strategic partnership that supports the clinical development and global expansion of Dupixent. The collaboration focuses on indication growth, reflected in the 2025 FDA approvals for bullous pemphigoid and chronic spontaneous urticaria, backed by trials such as LIBERTY-CSU CUPID. Investments in real-world data and pediatric formulations are contributing to market penetration across North America, Europe, and the Asia Pacific. In Latin America and the Middle East & Africa, patient access initiatives and pricing models are structured to address affordability constraints. The partnership’s regulatory capabilities and distribution network support efficient market entry and broader product availability.

Recent Developments

• In September 2024, The FDA approved Dupixent for adolescents with chronic obstructive pulmonary disease (COPD), expanding the eligible patient population. This approval targets 300,000 U.S. patients, with projected sales of USD 6 billion by 2030, driven by increasing COPD prevalence and demand for biologics.

• In November 2024, The FDA approved Dupixent for pediatric atopic dermatitis (6 months and older), expanding the market by 5%. This targets 1 million U.S. children, with expected sales growth of USD 1 billion by 2028.

• In June 2025, The FDA approved Dupixent for bullous pemphigoid, marking its eighth U.S. indication and the first targeted therapy for this rare skin disease affecting ~27,000 adults, primarily elderly. The approval, based on a pivotal trial demonstrating improved remission, reduced itch, and lower steroid use, expands Dupixent’s market potential.

U.S. Dupixent Market Report Scope

U.S. Dupixent Market Report Segmentation

This report forecasts revenue growth for the U.S. and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. dupixent market report based on indication and distribution channel:

• Indication Outlook (Revenue, USD Billion, 2021 - 2033)

  • Atopic Dermatitis (AD)

  • Asthma

  • Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

  • Chronic Obstructive Pulmonary Disease (COPD)

  • Others

• Distribution Channel Outlook (Revenue, USD Billion, 2021 - 2033)

  • Hospital Pharmacies

  • Retail Pharmacies

  • Others